3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
On October 8, 2026, Velo3D CEO Arun Jeldi posted on his personal X account that the company has no change to revenue guidance and no customer impact from recent changes. The post also said the company is progressing well toward year end, but the filing does not provide new financial results or quantify the recent changes.
CEO Arun Jeldi's X post, dated October 8, 2026, states there is no change in revenue guidance.
The post states there is no customer impact from recent changes, without describing those changes.
The filing furnishes the post as Exhibit 99.1 under Item 7.01 and does not include new financial figures.
Trinity Capital disclosed preliminary portfolio activity for the third quarter of 2026, with $880 million of new commitments and about $614 million of gross investments funded. The filing is a portfolio update, not full financial results, which the company will release on November 4, 2026.
Q3 2026 new commitments of about $880 million; first three quarters total $2.0 billion
Q3 gross investments funded of about $614 million, including $378 million in secured loans
Q3 gross repayments and exits of about $495 million; first three quarters total $1.1 billion
Full third quarter 2026 financial results and conference call scheduled for November 4, 2026 at 12:00 p.m. ET
Digital Asset Acquisition Corp. (DAAQ), a special purpose acquisition company, entered into a merger agreement on October 7, 2026 with Titan Strategics Holdings Ltd, whose subsidiary holds exploration permits for the Billingen Project in Sweden. The combined company is to be renamed Renaissance Nuclear, Inc. and the deal requires shareholder and regulatory approvals, with completion expected in early 2027. For DAAQ shareholders, the deal would issue 25,000,000 shares to Titan's equity holders and dilute existing holders, while the filing states that the historical uranium results have not yet been verified by a Qualified Person.
Base purchase price of $250,000,000, equal to 25,000,000 Parent Common Shares at $10.00 per share.
Titan's existing equity holders are expected to own about 70% of the combined company, excluding warrants, equity plan shares and any redemptions.
Expected gross transaction proceeds of about $65 million, including a minimum of $15 million PIPE investment.
Closing requires at least $10,000,000 of Parent Closing Cash and shareholder approval; completion is expected in early 2027.
On October 7, 2026, X4 Pharmaceuticals and its subsidiary X4 Therapeutics entered a Loan and Security Agreement with K2 HealthVentures providing term loans of up to $150.0 million. An $80.0 million first tranche funded at closing and was used to repay in full the Hercules loan, with a total payoff of approximately $78.7 million. For shareholders, the deal refinances existing debt and adds up to $70.0 million of possible further borrowing, but it carries variable-rate interest, secured liens, financial covenants, and a conversion feature that could issue common stock.
First tranche of $80.0 million funded October 7, 2026; up to $70.0 million more available at the company's request, subject to lender review and discretionary approval.
Hercules payoff of approximately $78.7 million, including $75.0 million of principal, ended the prior Hercules Loan Agreement and released its liens.
Cash interest is the greater of 8.55% or the WSJ prime rate plus 1.55%, plus 1.0% paid-in-kind interest; interest-only through October 1, 2029; maturity October 1, 2030.
Lenders may convert up to $15.0 million of principal into common stock at $3.2341 per share; minimum cash covenant applies from October 1, 2027 when market capitalization is below $800.0 million.
On October 2, 2026, Shimmick Corporation's subsidiary Shimmick Construction Company entered a Loan and Security Agreement with Sixty-First Commercial Finance for up to $14.3 million, due October 2, 2031, at 9.31% per annum. The company used the proceeds to fully repay and terminate its prior loan with Ansley Park Capital LLC, and it amended its revolving credit facility and ACF FINCO credit agreement to reference the new loan. Shareholders should note the loan is secured by equipment and related collateral and is guaranteed by the parent company.
Loan of up to $14.3 million from Sixty-First Commercial Finance, dated October 2, 2026, maturing October 2, 2031
Interest rate of 9.31% per annum; default rate up to the lesser of 15.0% or the legal maximum
Collateral includes specified equipment and related software, contracts, insurance rights and proceeds; Company and a subsidiary provide guaranties
Prior Ansley Park Capital LLC loan from March 12, 2025 was fully repaid and terminated on the same date
Silver Bow Mining Corp. issued a $5.0 million secured promissory note to Ocean Partners UK Limited for $5.0 million in cash on October 2, 2026, under a previously announced term sheet. The note is secured by a $28.58 million note from Montana Goldfields, Inc. and is required to be used to advance the Rainbow Block project and, once acquired, the Jefferson County Metallurgical Complex. The filing also reports a salary increase and bonuses for CEO C. Travis Naugle.
$5.0 million note sold to Ocean Partners UK Limited for $5.0 million in cash under a Note Purchase Agreement dated October 2, 2026
Interest at 12-month SOFR plus 6.75% a year, paid monthly from November 1, 2026; note matures March 31, 2027
If the Complex acquisition closes before maturity, the note is credited against a tranche A draw under a planned concentrate prepayment facility; otherwise principal and interest are due in a lump sum
CEO C. Travis Naugle's salary raised to $350,000 effective May 1, 2026, with a $250,000 one-time bonus and a $100,000 annual Executive Chairman payment
Byline Bancorp announced leadership changes under its succession plan, effective January 1, 2027. Sean H. McGuire becomes Chief Commercial Banking Officer and Scott Hawthorne becomes Chief Credit Officer, as Brogan Ptacin and Mark Fucinato retire effective December 31, 2026. The changes involve senior roles in commercial banking and credit risk, though the filing contains no financial results or guidance.
Brogan Ptacin, Head of Commercial Banking, retires effective December 31, 2026; Darrin Bacon succeeds him as Head of Commercial Banking effective January 1, 2027
Mark Fucinato, Chief Credit Officer, retires effective December 31, 2026; Scott Hawthorne succeeds him effective January 1, 2027
Sean H. McGuire, 58, is appointed to the newly created Chief Commercial Banking Officer role effective January 1, 2027
On October 8, 2026, the sponsor of DT Cloud Star Acquisition Corporation deposited a $75,000 extension payment into the company's trust account. The payment extends the deadline to complete an initial business combination by one month, to October 26, 2026. The filing is a routine extension step that keeps the blank-check company's search for a merger target on track.
Sponsor DT Cloud Star Management Limited deposited a $75,000 extension payment on October 8, 2026.
The payment moves the deadline to complete an initial business combination by one month, to October 26, 2026.
Nuveen Municipal Value Fund, Inc. disclosed that, effective October 30, 2026, it is supplementing its annual report with a new policy to invest at least 80% of its assets in municipal bonds that enhance portfolio value by delivering income. The filing also restates how the board may change policies, noting the new policy requires 60 days' prior written notice to shareholders before it can be changed.
New policy: at least 80% of assets in municipal bonds that enhance portfolio value by delivering income, effective October 30, 2026
Policy on tax-exempt municipal securities can only change with approval of a majority of common and preferred shares voting together, plus a majority of preferred shares voting separately
Filing dated October 8, 2026, signed by Mark L. Winget, Vice President and Secretary
Movado Group entered into a definitive agreement, effective October 5, 2026, to sell a 95% interest in its EBEL watch brand to a buyer group led by Montres Journe SA, with participation from Chanel and Pierre Jacques. Movado will keep a 5% stake, and the approximately $66.5 million consideration is subject to customary closing adjustments. The filing does not state EBEL's financial results or the expected effect of the sale on Movado's earnings.
Buyer group led by Montres Journe SA, with participation from Chanel and Pierre Jacques, who will serve as EBEL's CEO
Consideration expected to total approximately $66.5 million, subject to customary closing adjustments
Movado retains a 5% interest in EBEL
Closing expected in the fourth quarter of fiscal 2026, subject to customary conditions including a pre-closing reorganization
Cass Information Systems entered into an independent contractor agreement with Dwight Erdbruegger, who is retiring, to provide general consulting services through December 31, 2026. The agreement also fully vests his 2,318 time-based restricted stock units, which the filing notes were granted under a February 3, 2026 agreement.
Agreement dated October 7, 2026; term runs through December 31, 2026, terminable by either party on 30 days' notice
Consulting fee of $150.00 per hour, exclusive of taxes and fees, paid monthly
Full vesting of 2,318 time-based restricted stock units previously granted under a February 3, 2026 agreement
Includes customary non-competition, non-solicitation, confidentiality and intellectual property covenants; approved by the Compensation Committee
American Express and its bank subsidiary consented to orders from the Federal Reserve and the Office of the Comptroller of the Currency to resolve regulatory reviews of parts of its financial crimes compliance program. The bank unit also agreed to pay a $350 million civil money penalty, part of which was already reserved for in prior periods. The company says the penalty does not affect its 2026 guidance, and the orders impose no asset cap and are not expected to affect 2027 guidance.
Consent orders issued October 8, 2026 by the Federal Reserve and the OCC resolve previously disclosed reviews of financial crimes compliance.
American Express National Bank agreed to pay a $350 million civil money penalty to the OCC.
A portion of the penalty was reserved for in prior periods; the company says it does not affect full-year 2026 guidance.
The orders do not impose an asset cap, and remediation costs are not anticipated to affect 2027 guidance.
Payoneer director Barak Eilam resigned from the board and its Audit and Risk Committees, effective October 5, 2026, and the board size was set at seven members. The company also disclosed a $5,250,000 cash retention award for Chief Legal and Governance Officer Tsafi Goldman, tied to the pending merger agreement dated June 12, 2026.
Barak Eilam notified the company of his resignation on October 2, 2026, effective October 5, 2026
Eilam also left the Audit Committee and Risk Committee; board size fixed at seven members
Tsafi Goldman to receive a $5,250,000 cash retention award, to be granted in February 2027
Award vests in two equal installments: at Closing and on the first anniversary of Closing
OG&E's board named Chief Commercial Officer John Laws as its chief operating officer, effective January 4, 2027. The filing says Laws' compensation will be set in the standard annual officer review in December 2026, so no pay terms are disclosed yet.
John Laws, 52, named COO of OG&E by the board on October 5, 2026, effective January 4, 2027
Laws has been OG&E Chief Commercial Officer since January 2026
Previously Oklahoma Secretary of Budget and State CFO (October 2022 to December 2024) and Enable Midstream Partners EVP and CFO (2016 to 2021)
Compensation as COO to be set in December 2026 review
Super Micro Computer named Shesha Krishnapura, former Intel Chief Technology Officer, as an independent director effective October 9, 2026. Director Judy Lin, who has served since April 2022 and chairs the Nominating and Corporate Governance Committee, is retiring from the Board effective the same date.
Shesha Krishnapura joins the Board effective October 9, 2026 as an independent director, after a 35-year career at Intel Corporation.
Judy Lin retires from the Board effective October 9, 2026; she had served since April 2022 and chaired the Nominating and Corporate Governance Committee.
The filing states Ms. Lin's retirement was not the result of any disagreement with the Company on operations, policies or practices.
Mr. Krishnapura will receive the standard non-employee director compensation described in the fiscal 2026 Form 10-K.
GEO Group delivered a notice to redeem all $650.0 million of its 8.625% Senior Secured Notes due 2029, at about $678 million plus accrued interest, on October 15, 2026. The company said it will fund the redemption with net proceeds from recently announced asset sales. A new credit agreement extends the $550.0 million revolving facility to July 14, 2031 and allows unlimited share repurchases if the total leverage ratio is 2.25 to 1.00 or lower, which matters to shareholders because it expands the company's capacity to buy back stock.
Redemption of $650.0 million 2029 Senior Secured Notes at $1,043.13 per $1,000 principal, about $678 million, on October 15, 2026
Amended and Restated Credit Agreement closed October 5, 2026; $550.0 million revolver maturity extended to July 14, 2031
Share repurchases permitted without limit if pro forma total leverage ratio is 2.25 to 1.00 or lower and no default exists
Board approved a $750 million increase in the share repurchase program, from $500 million to $1.25 billion, effective through December 31, 2029
FS KKR Capital Corp. declared a fourth quarter 2026 regular distribution of $0.44 per share and a special distribution of $0.20 per share, both on October 7, 2026. The company also scheduled its third quarter 2026 results release and conference call for November 5, 2026, which is when shareholders will get the quarter's financial results.
Regular distribution of $0.44 per share, payable on or about December 24, 2026, to holders of record on December 16, 2026
Special distribution of $0.20 per share, payable on or about December 15, 2026, to holders of record on December 1, 2026
Third quarter 2026 results to be released before the New York Stock Exchange opens on November 5, 2026, with a 9:00 a.m. Eastern call
The Children's Place appointed Elizabeth A. LaPuma as an independent director and Audit Committee member effective October 2, 2026. Her term runs until the later of January 31, 2027 or completion of a restructuring and/or recapitalization transaction involving the company, and her pay is set under a letter agreement with Claritas Advisors LLC, which includes a guaranteed minimum of $193,500.
Appointed effective October 2, 2026; qualifies as an audit committee financial expert under SEC and Nasdaq rules
Term ends at the later of January 31, 2027 or consummation of a restructuring and/or recapitalization transaction
Letter agreement with Claritas Advisors LLC, effective September 22, 2026: $13,500 on the effective date, $45,000 monthly, guaranteed minimum $193,500
Terra Innovatum Global N.V. disclosed that director Cesare Frepoli notified the company on October 2, 2026 that he is resigning from the board, effective that day. He will remain Chief Operating Officer and Co-Chief Executive Officer of the company's U.S. Subsidiary, and the company says the resignation is solely to keep the board majority independent under NASDAQ Listing Rule 5605(b).
Resignation from the board of directors effective October 2, 2026
Frepoli remains Chief Operating Officer and Co-Chief Executive Officer of the U.S. Subsidiary
Stated purpose: keep the board majority independent as required by NASDAQ Listing Rule 5605(b)
MFA Financial announced that CEO Craig Knutson will retire effective June 30, 2027, and that President and Chief Investment Officer Bryan Wulfsohn will succeed him as CEO effective July 1, 2027. Wulfsohn will join the Board effective January 1, 2027, and Andrew Kail will join as Chief Investment Officer on the same date, giving shareholders a defined leadership transition timeline.
Craig Knutson, 67, retires as CEO effective June 30, 2027, and is expected to remain on the Board and stand for reelection in 2027
Bryan Wulfsohn, 43, becomes CEO effective July 1, 2027, and joins the Board effective January 1, 2027, increasing the Board to eight directors
Andrew P. Kail joins as Senior Vice President and Chief Investment Officer effective January 1, 2027
Wulfsohn's 2027 Overall Target Bonus is $1,700,000 and his 2027 TRSU and PRSU grant values are $1,160,000 and $1,740,000; Knutson's 2027 equity grants are cut 50% to $843,000 (TRSUs) and $1,264,500 (PRSUs)
Hercules Capital, Inc. closed the sale of $400 million in aggregate principal amount of 6.700% Notes due October 8, 2029, on October 8, 2026, under a previously announced public offering. The company expects to use the net proceeds to repay outstanding indebtedness, fund investments and for general corporate purposes, which adds fixed-rate debt to its balance sheet.
Principal amount: $400 million; interest of 6.700% per year, paid semiannually on April 8 and October 8, starting April 8, 2027
Maturity: October 8, 2029, unless previously redeemed or repurchased
Notes are unsecured and rank senior to subordinated debt, but effectively rank junior to secured indebtedness
Underwriting agreement dated October 5, 2026 with Goldman Sachs & Co. LLC and SMBC Nikko Securities America, Inc. as representatives; trustee is U.S. Bank Trust Company, National Association
Sezzle Inc. announced it will release its third quarter 2026 results after the market close on November 4, 2026, and hold a conference call at 5:00 p.m. Eastern Time that day. The filing contains no financial results, so it does not show revenue, profit, or guidance; it only sets the date for the results and call.
Third quarter 2026 results release: after market close on Wednesday, November 4, 2026
Conference call and webcast: 5:00 p.m. Eastern Time, November 4, 2026
Management will attend investor conferences from November 9 to December 9, 2026, including BMO, Citi, KBW, TD Cowen and Needham events
Gartner said Executive Vice President, Chief Legal Officer and Secretary Thomas Kim will leave his role effective October 16, 2026, to pursue a new senior executive opportunity. The filing states there was no disagreement with the company on financials, operations, policies or practices, and it does not name a successor.
Thomas Kim notified Gartner on October 3, 2026 that he will step down
Departure takes effect October 16, 2026
Kim is EVP, Chief Legal Officer and Secretary; he is leaving for a new senior executive opportunity
Filing states no disagreement with Gartner on financials, operations, policies or practices
Aardvark Therapeutics appointed David Zhang as a Class II director effective October 7, 2026, and announced the appointment in a press release dated October 8, 2026. The company describes him as an independent director and says he will help navigate the regulatory path for ARD-101 and shape its next phase of development for Prader-Willi Syndrome.
Appointed by the board on October 6, 2026, effective October 7, 2026, as a Class II director
Non-employee director cash compensation of $40,000 per year, prorated for time served
Option grant on October 7, 2026 sized at $500,000, vesting monthly over 36 months
Dr. Zhang is Chief Strategy Officer of Abivax S.A.; previously held roles at Alumis Inc. and MyoKardia, Inc.
Quantum-Si said it has demonstrated detection of 19 amino acids in its Proteus development program and is now working to deploy that capability into a developmental sequencing kit for R&D use. The company reaffirmed its target of demonstrating detection of all 20 amino acids by year-end 2026 and its planned commercial launch of Proteus in the second quarter of 2027, but the filing contains no financial results.
Detection of 19 amino acids demonstrated in the Proteus development program, announced October 8, 2026
Previously, a developmental kit detecting 18 amino acids was presented at the 2026 World HUPO Congress
Company target is detection of all 20 amino acids by year-end 2026
Proteus commercial launch is planned for the second quarter of 2027
On October 5, 2026, Werner entered into a $1.1 billion unsecured credit facility maturing October 5, 2031, and used it to pay off the $428 million outstanding under its 2022 facility, which had been due December 20, 2027. The company borrowed $465 million at a weighted average rate of 5.54%, and the filing says the new facility removed the 0.10% credit adjustment spread that applied under the old one.
New $1.1 billion facility matures October 5, 2031, replacing the $1.075 billion facility dated December 20, 2022
$465 million drawn at a weighted average rate of 5.54%, based on SOFR plus 1.50%
As of October 5, 2026, total debt was $840 million; remaining borrowing capacity was $603.1 million
Facility includes a maximum net funded debt to Covenant Defined EBITDA ratio and a minimum EBITDA to interest expense ratio
Onterris, Inc. disclosed that director Janet Risi Field resigned from its Board of Directors on October 7, 2026, effective immediately. The company said her decision was for personal reasons and not due to any disagreement with the company on its operations, policies or practices.
Resignation dated October 7, 2026, effective immediately
Filing states the reason was personal, with no disagreement with the company
Filing made under Item 5.02 and signed by General Counsel and Secretary Nasym Afsari on October 8, 2026
Patricia E. Lopez notified Domino's Pizza on October 2, 2026, that she will retire from the Board of Directors effective October 7, 2026. She said the decision is for personal reasons and not due to any disagreement with the company's operations, policies or practices.
Patricia E. Lopez retires from the Board effective October 7, 2026
Notice given to the company on October 2, 2026
Company states retirement is for personal reasons, with no disagreement over operations, policies or practices
On October 5, 2026, the Audit Committee dismissed WithumSmith+Brown as Elauwit Connection's independent auditor, effective immediately, and engaged MPB Global LLP for the fiscal year ending December 31, 2026. The filing says WithumSmith+Brown issued no report after March 31, 2026 on the 2025 financial statements, and it cites material weaknesses in internal control over financial reporting disclosed in the company's 2025 Form 10-K. Shareholders may want to watch for the new auditor's work and any further disclosure about those weaknesses.
Audit Committee approved the dismissal of WithumSmith+Brown on October 5, 2026, effective immediately.
WithumSmith+Brown was engaged August 26, 2025, and did not issue a report after March 31, 2026 on the 2025 financial statements.
Its 2025 audit report had no adverse opinion or disclaimer and was not qualified or modified.
MPB Global LLP was engaged on October 5, 2026, as the new auditor for fiscal 2026; the filing cites material weaknesses in internal control from the 2025 Form 10-K.
AGNT, Inc. said its founder and Chief Executive Officer, Glenn Sanford, will step down as CEO effective October 8, 2026, and remain Chairman of the Board. The Board unanimously appointed Leo Pareja, CEO of eXp Realty since April 2024, as CEO effective the same date, and he signed an employment agreement with a five-year initial term. Shareholders should note the new CEO's pay package, including a base salary increase to $1,800,000 and a promotional equity grant.
Leo Pareja becomes CEO effective October 8, 2026; the Board approved the appointment on October 6, 2026.
Pareja's annual base salary rises to $1,800,000 under the Employment Agreement.
Promotional grant includes a stock option covering 1,060,814 shares at target, with vesting of 0% to 200% based on relative total shareholder return, and 573,588 restricted stock units.
The 2027 annual equity award has a grant-date value of $4,897,500; Sanford will receive the standard non-employee director compensation package as Chairman.
Kirby Corporation said its Vice President, Controller and Assistant Secretary, Ronald A. Dragg, intends to retire in the first quarter of 2027, after the Company files its 2026 Form 10-K. He will keep his current roles through the transition, and the filing says his retirement does not involve any disagreement with the Company on operations, accounting or controls.
Ronald A. Dragg, 62, notified the Company on October 6, 2026 of his plan to retire.
Retirement is planned for the first quarter of 2027, after the 2026 Form 10-K is filed.
Dragg will continue in his positions and help ensure an orderly transition.
Compensation terms for the retirement have not been set; the Company will file an amended 8-K if a material arrangement is approved.
MSC Income Fund disclosed private loan portfolio activity for the third quarter of 2026 in a press release furnished under Item 2.02. The filing reports new or increased commitments of $62.2 million and funded investments at cost of $61.4 million, with the portfolio at $849.6 million across 81 companies as of September 30, 2026. The release does not include earnings, net asset value, or guidance, so it gives shareholders portfolio activity rather than a full results update.
Q3 2026 private loan commitments originated or increased: $62.2 million
Q3 2026 funded investments at cost basis: $61.4 million
Private loan portfolio at cost as of September 30, 2026: $849.6 million across 81 companies
Portfolio mix: 90.1% first lien senior secured debt, 9.9% equity or other securities
Charlton Aria Acquisition Corp furnished an investor presentation and script for its proposed business combination with KQC Quantum, Inc., which was agreed on October 6, 2026. A joint webcast is scheduled for 10:30 a.m. Eastern Time on October 8, 2026. The deck shows a $80.0 million pre-money equity valuation and a trust balance of about $93.5 million before redemptions, so the amount of cash available at closing will depend on shareholder redemptions.
Pre-money KQC Parent equity valuation of $80.0 million; minimum cash condition of $30.0 million
Trust held about $93.5 million at September 25, 2026, or $11.00 per public share, before redemptions
Maximum redemption consistent with the minimum cash condition is about 68% of public shares; target closing in H1 CY27
Joint investor webcast at 10:30 a.m. Eastern Time on Thursday, October 8, 2026
Viatris signed a merger agreement on October 8, 2026 to acquire Pacira BioSciences through a cash tender offer at $36.50 per share, an aggregate equity value of $1.65 billion. Viatris said it expects to fund the deal primarily from excess cash, with the rest from short-term borrowings, and expects it to be immediately accretive to its financial guidance metrics and to close by the end of 2026. The deal is a large acquisition that would add Pacira's marketed EXPAREL and ZILRETTA products to Viatris.
Offer price of $36.50 per share in cash; aggregate equity value of $1.65 billion per the joint press release.
Pacira generated approximately $746 million in total revenue and $177 million in adjusted EBITDA for the twelve months ended June 30, 2026.
Completion requires a majority of Pacira shares tendered; the offer is open for 10 business days, and the merger agreement's outside date is April 8, 2027.
Pacira would pay Viatris a $62 million termination fee under specified circumstances, including a Superior Offer.
NN, Inc. redeemed all 18,400 remaining shares of its Series D Perpetual Preferred Stock on October 7, 2026, for about $30.7 million in cash, ending the holder's rights including its board observer rights. The payment reflects a $5.0 million reduction under an August 5, 2026 exchange agreement, and the company said the redemption was funded by a $53.1 million private placement completed October 5, 2026. The company said it will provide updated guidance on its October 29, 2026 earnings call.
18,400 Series D preferred shares redeemed on October 7, 2026, for about $30.7 million
The $5.0 million reduction under the August 5, 2026 Exchange Agreement with NHTV Nevada Holdings LP lowered the payment from the $35.7 million security value
Funded by proceeds from a $53.1 million PIPE placement completed October 5, 2026
No Series D preferred shares remain outstanding; updated guidance is due on the October 29, 2026 earnings call
At its 2026 Investor Day on October 8, 2026, Mission Produce presented five-year financial targets and an ambition to double sales and triple Adjusted EBITDA by 2035. The company also reaffirmed its second-half and fourth-quarter fiscal 2026 outlook and disclosed fiscal fourth-quarter-to-date share repurchases under its $100 million authorization.
Five-year targets include mid-single-digit organic sales growth and approximately 300 basis points of margin expansion, with a 2035 ambition to double sales and triple Adjusted EBITDA.
Reaffirmed second-half fiscal 2026 Adjusted EBITDA of $84 million to $88 million, including fourth-quarter Adjusted EBITDA of $52 million to $55 million.
Fiscal fourth-quarter-to-date repurchases of 290,994 shares at an average price of $12.94, under the $100 million program authorized June 8, 2026.
Calavo integration has increased the annualized synergy target to more than $30 million from at least $25 million.
AquaBounty Technologies agreed on October 7, 2026, that all outstanding Series A and Series B preferred shares will automatically convert into common stock. The company will issue 8,077,043 common shares to the preferred holders, who paid no additional consideration, which adds to the common shares that existing shareholders hold.
Conversion occurs on the earlier of SEC effectiveness of the resale registration statement or October 30, 2026
Shares issued: 5,771,929 for Series A and 2,305,114 for Series B, totaling 8,077,043 common shares
Conversion prices: $0.9129 per share for Series A and $1.03 per share for Series B; holders waived dividends accruing after October 15, 2026
The company will file a Form S-3 resale registration, kept effective until the earliest of full resale, Rule 144 eligibility, or the second anniversary of the Conversion Date
ConnectOne Bancorp announced it will release its third quarter 2026 results, for the quarter ended September 30, 2026, before the market opens on Thursday, October 22, 2026. Management will host a conference call and audio webcast the same day at 10:00 a.m. ET. The announcement sets the timing for shareholders to review the quarter's financial performance; it does not itself include any results.
Third quarter 2026 results, for the quarter ended September 30, 2026, to be released before market open on October 22, 2026
Conference call and audio webcast at 10:00 a.m. ET on October 22, 2026, hosted by Chairman and CEO Frank Sorrentino III and CFO William S. Burns
Webcast available via the Investor Relations section of the company website, with an archive after the call
Virginia National Bankshares Corporation announced a share repurchase plan authorizing up to $18.7 million of its common stock through October 5, 2027. The plan gives the company flexibility to buy shares in the open market or in private transactions, but it does not require any specific amount of purchases.
Authorization: up to $18.7 million of common stock, par value $2.50 per share
Plan period: announced October 6, 2026, running through October 5, 2027
Repurchases may be made in the open market, privately negotiated transactions or otherwise, depending on market conditions and corporate needs
The company may be extended, modified, suspended or discontinued at any time at its discretion
AngioDynamics said Eric Honroth will become President and Chief Executive Officer and a director effective November 2, 2026, succeeding James Clemmer, who has led the company since April 2016 and is retiring. The filing also sets Honroth's pay, including a $735,000 base salary and a $350,000 sign-on bonus, and a $30,000 monthly consulting arrangement for Clemmer for one year.
Eric Honroth, 55, most recently served as President Life Science at Getinge AB from 2018 to 2026.
Honroth's base salary is $735,000, with a target annual bonus of 95% of base salary.
Honroth receives a $350,000 cash sign-on bonus, repayable if he leaves without Good Reason or is terminated for Cause within the first year.
Clemmer will consult for the company for one year at $30,000 per month; Howard Donnelly plans to retire as a Class II director at the end of his current term.
Shoulder Innovations announced a limited user release of the InSet Go, its next-generation glenoid implant, after the first surgical case was completed at University Hospitals Cleveland Medical Center. The filing contains no financial figures, and the company said it expects a full commercial introduction over the coming quarters, so the news is an early step in the product's rollout.
First surgical case using InSet Go was performed by Robert Gillespie, MD, at University Hospitals Cleveland Medical Center, Cleveland, OH
The company says InSet Go reduces surgical steps and offers the potential for reduced procedure times
Full commercial introduction is expected over the coming quarters, according to CEO Rob Ball
The filing reports no revenue, earnings or guidance figures
Editas Medicine said it received approval to start the Phase 1/2 Strive trial of its experimental gene editing medicine EDIT-401 in patients with heterozygous familial hypercholesterolemia in Australia, and submitted the trial for review in New Zealand. The filing states that the company expects to report initial safety and tolerability data in the first quarter of 2027, with topline safety and efficacy data later in 2027, so the program is still at an early clinical stage with no financial results attached.
Trial received Human Research Ethics Committee approval and completed the Clinical Trial Notification process with Australia's Therapeutic Goods Administration
Trial has been submitted for review in New Zealand; patients in both countries would be eligible to enroll if approved there
Initial safety and tolerability data expected in the first quarter of 2027
New preclinical data on LDL-C reduction will be presented at the AHA Scientific Sessions on November 8, 2026
Vontier said Kathryn Rowen, its Executive Vice President and Chief Transformation and Operations Officer, notified the company on October 2, 2026 that she will resign effective October 16, 2026 to pursue another opportunity. The filing does not name a successor or describe any financial effect, so its impact on shareholders is not stated.
Kathryn Rowen, EVP and Chief Transformation and Operations Officer, gave notice on October 2, 2026
Resignation takes effect October 16, 2026
She is leaving to pursue another opportunity; no successor is named in the filing
Henry Schein said former ITT CFO Emmanuel Caprais will become its Senior Vice President and Chief Financial Officer effective November 4, 2026, succeeding Ronald N. South, who moves to a Senior Advisor role on that date. Mr. Caprais joins as Senior Financial Advisor on October 12, 2026, and Mr. South remains CFO through November 3, 2026, including the third quarter earnings process. The filing describes a planned, structured handover of the finance chief role rather than a financial result.
Emmanuel Caprais, 51, most recently served as CFO of ITT Inc. from 2020 to May 2026; he will report to CEO Frederick M. Lowery
Offer Letter sets a $750,000 base salary, a $750,000 target annual bonus, and a $25,000 sign-on bonus
Expected 2027 long-term incentive award has an estimated grant date fair value of $2,500,000, plus a $250,000 one-time sign-on equity award granted in December 2026
Ronald N. South has served at Henry Schein for 18 years and as CFO for the past four years
On October 7, 2026, Atrium Therapeutics agreed to sell 5,170,384 common shares at $7.93 each, plus pre-funded warrants for up to 1,134,930 shares, to accredited investors, for expected gross proceeds of about $50 million before fees. The company says the proceeds, together with existing cash, will fund operations through 2028, and that shares outstanding will rise to 22,276,027 after the offering, which shareholders should weigh against their stake.
5,170,384 common shares sold at $7.93 per share; pre-funded warrants for up to 1,134,930 shares sold at $7.929 each.
Expected gross proceeds of about $50 million before placement agent fees and offering expenses; closing expected on or about October 9, 2026.
Company estimates net proceeds plus existing cash will fund operations through 2028; proceeds are for lead programs, other research, working capital and general corporate purposes.
Company must file a resale registration statement with the SEC within 50 days of the closing date; 22,276,027 shares will be outstanding after the offering.
Nova Minerals said all key equipment for its planned antimony processing and refinery has arrived at Port MacKenzie, Alaska, and construction of the facility can begin in the coming weeks, subject to remaining permits. The company also said its 2026 Estelle field season has concluded, with assay results from the drilling still pending, and the project is backed by a $43.4 million U.S. Department of War award.
Final major equipment for the antimony processing and refinery arrived at Port MacKenzie on October 6, 2026.
Construction of the facility is expected to begin in the coming weeks, subject to receipt of the remaining permits.
The 2026 Estelle field season, with about 8,000m of diamond drilling, is complete; initial assay results are expected in due course.
The project is supported by a $43.4 million U.S. Department of War award, with first antimony expected in 2027.
Perspective Therapeutics (NYSE American: CATX) announced on October 8, 2026 that the U.S. Food and Drug Administration granted Fast Track Designation for PSV359 for adult patients with locally advanced unresectable and/or metastatic FAP-positive solitary fibrous tumors. The filing says the designation is intended to facilitate development and expedite review, and that PSV359 is in an ongoing Phase 1/2a study, but it does not describe any financial effect.
FDA granted Fast Track Designation for PSV359 on or before October 8, 2026, per the press release dated October 8, 2026.
The designation covers adult patients with locally advanced unresectable and/or metastatic FAP-positive solitary fibrous tumors.
PSV359 is an investigational FAP-targeted alpha-particle therapy being evaluated in an ongoing Phase 1/2a study (NCT06710756).
The press release is filed as Exhibit 99.1; the filing reports no financial figures.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.